Baker Tilly Wealth Management LLC Sells 647 Shares of Johnson & Johnson (NYSE:JNJ)

Baker Tilly Wealth Management LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 10.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,783 shares of the company’s stock after selling 647 shares during the quarter. Baker Tilly Wealth Management LLC’s holdings in Johnson & Johnson were worth $836,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Legacy Private Trust Co. grew its holdings in Johnson & Johnson by 8.4% during the 4th quarter. Legacy Private Trust Co. now owns 39,173 shares of the company’s stock worth $5,665,000 after acquiring an additional 3,047 shares during the period. Douglas Lane & Associates LLC boosted its holdings in Johnson & Johnson by 1.1% during the fourth quarter. Douglas Lane & Associates LLC now owns 599,386 shares of the company’s stock worth $86,683,000 after buying an additional 6,526 shares during the last quarter. InvesTrust bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $6,355,000. Fulton Bank N.A. boosted its stake in Johnson & Johnson by 7.8% during the 4th quarter. Fulton Bank N.A. now owns 47,550 shares of the company’s stock worth $6,877,000 after acquiring an additional 3,427 shares during the last quarter. Finally, Innova Wealth Partners acquired a new position in Johnson & Johnson during the fourth quarter valued at approximately $416,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently commented on JNJ shares. Morgan Stanley raised their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Bank of America reissued a “neutral” rating and set a $166.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, December 10th. Guggenheim lifted their target price on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Royal Bank of Canada upped their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $174.71.

Insider Activity

In related news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

NYSE JNJ traded up $0.13 during midday trading on Friday, hitting $142.40. The company had a trading volume of 2,037,144 shares, compared to its average volume of 6,854,486. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company has a market capitalization of $342.85 billion, a PE ratio of 20.61, a P/E/G ratio of 2.52 and a beta of 0.51. The firm has a 50-day moving average price of $150.03 and a 200-day moving average price of $156.04.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same period last year, the firm posted $2.66 earnings per share. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. As a group, analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.48%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.